| human | Q5 |
| P496 | ORCID iD | 0000-0001-9043-538X |
| P106 | occupation | researcher | Q1650915 |
| Q91107037 | A Young Man with a Mass: Non-Early Precursor T-Cell Lymphoblastic Lymphoma |
| Q42104186 | Acute appendicitis caused by Schistosoma japonicum. |
| Q40181184 | Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia |
| Q103811897 | Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-Intensity Induction with Venetoclax |
| Q93062406 | Long-term results of frontline dasatinib in chronic myeloid leukemia |
| Q42365051 | Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy |
| Q48036216 | Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. |
| Q54839818 | Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. |
| Q91009142 | Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia |
| Q46976339 | Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia |
| Q90460345 | Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial |
| Q47678627 | Vasculitis due to levamisole-adulterated cocaine. |
| Q103829076 | Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality |
Search more.